The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers
Open accessAbstract
To compare the survival of women with uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC) to those with grade 3 endometrioid uterine carcinoma (G3EC). Demographic, pathologic, treatment, and survival information were obtained from the Surveillance, Epidemiology, and End Results Program from 1988 to 2001. Data were analysed using Kaplan-Meier and Cox proportional hazards regression methods. Of 4180 women, 1473 had UPSC, 391 had CC, and 2316 had G3EC cancers. Uterine papillary serous carcinoma and CC patients were older (median age: 70 years and 68 vs 66 years, respectively; P<0.0001) and more likely to be black compared to G3EC (15 and 12% vs 7%; P<0.0001). A higher proportion of UPSC and CC patients had stage III-IV disease compared to G3EC patients (52 and 36% vs 29%; P<0.0001). Uterine papillary serous carcinoma, CC and G3EC patients represent 10, 3, and 15% of endometrial cancers but account for 39, 8, and 27% of cancer deaths, respectively. The 5-year disease-specific survivals for women with UPSC, CC and G3EC were 55, 68, and 77%, respectively (P<0.0001). The survival differences between UPSC, CC and G3EC persist after controlling for stage I-II (74, 82, and 86%; P<0.0001) and stage III-IV disease (33, 40, and 54; P<0.0001). On multivariate analysis, more favourable histology (G3EC), younger age, and earlier stage were independent predictors of improved survival. Women with UPSC and CC of the uterus have a significantly poorer prognosis compared to those with G3EC. These findings should be considered in the counselling, treating and designing of future trials for these high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study
Creasman, W. T., Morrow, C. P., Bundy, B. N., Homesley, H. D., Graham, J. E., & Heller, P. B. (1987) · Cancer · doi:10.1002/1097-0142(19901015)60:8+<2035::aid-cncr2820601515>3.0.co;2-8 · Cited by 1,963
Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., & Bell, J. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.048 · Cited by 1,671
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
The surveillance, epidemiology, and end results program: a national resource.
Hankey, B. F., Ries, L. A. G., & Edwards, B. K. (1999) · PubMed · Cited by 594
Clement, P. B., & Young, R. H. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200205000-00001 · Cited by 280
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
Creasman, W. T., Kohler, M. F., Odicino, F., Maisonneuve, P., & Boyle, P. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.019 · Cited by 256
Cirisano, F. D., Robboy, S. J., Dodge, R. K., Bentley, R. C., Krigman, H. R., Synan, I. S., Soper, J. T., & Clarke-Pearson, D. L. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5505 · Cited by 199
McMeekin, D. S., Filiaci, V. L., Thigpen, J. T., Gallion, H. H., Fleming, G. F., & Rodgers, W. H. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.04.032 · Cited by 172
Cited by
Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 516
NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Le Gallo, M., O'Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O'Neil, N. J., Price, J. C., Zhang, S., England, B. M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 419
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
Gilks, C. B., Oliva, E., & Soslow, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f576a · Cited by 401
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 397
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S., Secord, A. A., Havrilesky, L., O'Malley, D. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0953 · Cited by 314
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Factors associated with Type I and Type II endometrial cancer
Felix, A. S., Weissfeld, J. L., Stone, R. A., Bowser, R., Chivukula, M., Edwards, R. P., & Linkov, F. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9612-8 · Cited by 284
Murali, R., Davidson, B., Fadare, O., Carlson, J. A., Crum, C. P., Gilks, C. B., Irving, J. A., Malpica, A., Matias-Guiu, X., McCluggage, W. G., et al. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000491 · Cited by 278
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
Boruta, D. M., Gehrig, P. A., Fader, A. N., & Olawaiye, A. B. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.06.011 · Cited by 254
Management of women with clear cell endometrial cancer
Olawaiye, A. B., & Boruta, D. M. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.02.003 · Cited by 124
Metadata
- Authors
- Hamilton, C. A., Cheung, M. K., Osann, K., Chen, L., Teng, N. N., Longacre, T. A., Powell, M. A., Hendrickson, M. R., Kapp, D. S., & Chan, J. K.
- Venue
- British Journal of Cancer
- Published
- 2006-02-21
- Volume
- 94
- Issue
- 5
- Pages
- 642-646
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2065949107
- Cited by
- 644
- References
- 21
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.